Cargando…
Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma
Multiple myeloma (MM) is a plasma cell malignancy for which there is currently no cure. While treatment options for MM have expanded over the last two decades, all patients will eventually become resistant to current therapies. Thus, there is an urgent need for novel therapeutic strategies to treat...
Autores principales: | Haney, Staci L., Holstein, Sarah A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820492/ https://www.ncbi.nlm.nih.gov/pubmed/36613550 http://dx.doi.org/10.3390/ijms24010111 |
Ejemplares similares
-
Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells
por: Dykstra, Kaitlyn M., et al.
Publicado: (2015) -
Exploring Drug Targets in Isoprenoid Biosynthetic Pathway for Plasmodium falciparum
por: Qidwai, Tabish, et al.
Publicado: (2014) -
Simultaneous Quantitation of Isoprenoid Pyrophosphates in Plasma and Cancer Cells Using LC-MS/MS
por: Chhonker, Yashpal S., et al.
Publicado: (2018) -
Retracted: Exploring Drug Targets in Isoprenoid Biosynthetic Pathway for Plasmodium falciparum
por: International, Biochemistry Research
Publicado: (2022) -
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
por: Haney, Staci L., et al.
Publicado: (2022)